Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas

Research output: Contribution to journalArticle

Abstract

The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas has been demonstrated in epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan and southern parts of United States. Marginal zone lymphomas are the histotypes that are most frequently associated with HCV infection. The WHO classification comprises extranodal marginal zone B-cell lymphoma of MALT type, splenic marginal zone B-cell lymphoma and nodal marginal zone B-cell lymphoma. Recently, antiviral treatment has been proved to be effective in the treatment of HCV-positive patients with indolent lymphoma, prevalently of marginal zone origin. This is the strongest evidence of a causative link between HCV and lymphomas. Aim of this review is to illustrate the relationship between HCV infection and marginal zone lymphomas and to systematically summarize the data from the therapeutic studies where antiviral treatment with aα-interferon with or without ribavirin was employed in patients with marginal zone lymphomas.

Original languageEnglish
Pages (from-to)74-81
Number of pages8
JournalCurrent Clinical Pharmacology
Volume5
Issue number2
DOIs
Publication statusPublished - May 2010

Fingerprint

Virus Diseases
Hepacivirus
Antiviral Agents
Lymphoma
Marginal Zone B-Cell Lymphoma
Therapeutics
Ribavirin
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Interferons
Italy
Epidemiologic Studies
Japan

Keywords

  • Hepatitis C virus
  • Interferon
  • MALT
  • Marginal zone lymphomas
  • Ribavirin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. / Arcaini, Luca; Bruno, Raffaele.

In: Current Clinical Pharmacology, Vol. 5, No. 2, 05.2010, p. 74-81.

Research output: Contribution to journalArticle

@article{a4f2cd750e9c42dbbe1feddf73c0ad2a,
title = "Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas",
abstract = "The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas has been demonstrated in epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan and southern parts of United States. Marginal zone lymphomas are the histotypes that are most frequently associated with HCV infection. The WHO classification comprises extranodal marginal zone B-cell lymphoma of MALT type, splenic marginal zone B-cell lymphoma and nodal marginal zone B-cell lymphoma. Recently, antiviral treatment has been proved to be effective in the treatment of HCV-positive patients with indolent lymphoma, prevalently of marginal zone origin. This is the strongest evidence of a causative link between HCV and lymphomas. Aim of this review is to illustrate the relationship between HCV infection and marginal zone lymphomas and to systematically summarize the data from the therapeutic studies where antiviral treatment with aα-interferon with or without ribavirin was employed in patients with marginal zone lymphomas.",
keywords = "Hepatitis C virus, Interferon, MALT, Marginal zone lymphomas, Ribavirin",
author = "Luca Arcaini and Raffaele Bruno",
year = "2010",
month = "5",
doi = "10.2174/157488410791110751",
language = "English",
volume = "5",
pages = "74--81",
journal = "Current Clinical Pharmacology",
issn = "1574-8847",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas

AU - Arcaini, Luca

AU - Bruno, Raffaele

PY - 2010/5

Y1 - 2010/5

N2 - The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas has been demonstrated in epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan and southern parts of United States. Marginal zone lymphomas are the histotypes that are most frequently associated with HCV infection. The WHO classification comprises extranodal marginal zone B-cell lymphoma of MALT type, splenic marginal zone B-cell lymphoma and nodal marginal zone B-cell lymphoma. Recently, antiviral treatment has been proved to be effective in the treatment of HCV-positive patients with indolent lymphoma, prevalently of marginal zone origin. This is the strongest evidence of a causative link between HCV and lymphomas. Aim of this review is to illustrate the relationship between HCV infection and marginal zone lymphomas and to systematically summarize the data from the therapeutic studies where antiviral treatment with aα-interferon with or without ribavirin was employed in patients with marginal zone lymphomas.

AB - The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas has been demonstrated in epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan and southern parts of United States. Marginal zone lymphomas are the histotypes that are most frequently associated with HCV infection. The WHO classification comprises extranodal marginal zone B-cell lymphoma of MALT type, splenic marginal zone B-cell lymphoma and nodal marginal zone B-cell lymphoma. Recently, antiviral treatment has been proved to be effective in the treatment of HCV-positive patients with indolent lymphoma, prevalently of marginal zone origin. This is the strongest evidence of a causative link between HCV and lymphomas. Aim of this review is to illustrate the relationship between HCV infection and marginal zone lymphomas and to systematically summarize the data from the therapeutic studies where antiviral treatment with aα-interferon with or without ribavirin was employed in patients with marginal zone lymphomas.

KW - Hepatitis C virus

KW - Interferon

KW - MALT

KW - Marginal zone lymphomas

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=77951645097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951645097&partnerID=8YFLogxK

U2 - 10.2174/157488410791110751

DO - 10.2174/157488410791110751

M3 - Article

C2 - 20156155

AN - SCOPUS:77951645097

VL - 5

SP - 74

EP - 81

JO - Current Clinical Pharmacology

JF - Current Clinical Pharmacology

SN - 1574-8847

IS - 2

ER -